The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma
Abstract
BACKGROUND: The current systematic review and meta‐analysis compared monotherapy and combined androgen blockade in the treatment of men with advanced prostate carcinoma. Outcomes of interest included overall, cancer specific, and progression‐free survival; time to treatment failure; adverse events; and quality of life. METHODS: The literature search identified randomized trials comparing monotherapy (orchiectomy and luteinizing hormone‐releasing hormone [LHRH] agonists) with combination therapy using orchiectomy or a LHRH agonist plus a nonsteroidal or steroidal antiandrogen. Dual independent review occurred. The meta‐analysis used a random effects model. RESULTS: Twenty‐one trials compared survival after monotherapy with survival after combined androgen blockade (n = 6871 patients). The meta‐analysis found no statistically significant difference in survival at 2 years between patients treated with combined androgen blockade and those treated with monotherapy (20 trials; hazard ratio [HR] = 0.970; 95% confidence interval [95% CI], 0.866–1.087). The authors determined a statistically significant difference in survival at 5 years that favored combined androgen blockade (10 trials; HR = 0.871; 95% CI, 0.805–0.942). For the subgroup of patients with a good prognosis, there was no statistically significant difference in survival. Adverse effects leading to withdrawal from therapy occurred more often with combined androgen blockade. To the authors' knowledge there is little evidence published to date comparing the effects of combined androgen blockade and monotherapy on quality of life, but the single randomized trial that adequately addressed this outcome reported an advantage for monotherapy over combined androgen blockade. CONCLUSIONS: A thorough examination of the usefulness of combined androgen blockade must balance the modest increase in expected survival observed at 5 years against the increased risk of adverse effects and the potential for adversely affecting the patient's overall quality of life. [See editorial on pages 209–10, this issue.] Cancer 2002;95:361–76. © 2002 American Cancer Society. DOI 10.1002/cncr.10647
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391504 · Cited by 859
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials
(2000) · The Lancet · doi:10.1016/s0140-6736(00)02163-2 · Cited by 819
A general parametric approach to the meta‐analysis of randomized clinical trials
Whitehead, A., & Whitehead, J. (1991) · Statistics in Medicine · doi:10.1002/sim.4780101105 · Cited by 750
Cochrane Collaboration Handbook
Mulrow, C. (1996) · Medical Entomology and Zoology · Cited by 403
LITWIN, M. S., LUBECK, D. P., HENNING, J. M., & CARROLL, P. R. (1998) · Journal of Urology · doi:10.1016/s0022-5347(01)63222-1 · Cited by 401
Moher, Cook, Jadad, Tugwell, Moher, Jones, Pham, & Klassen (1999) · Health Technology Assessment · doi:10.3310/hta3120 · Cited by 368
Labrie, F., Dupont, A., Bèlanger, A., Cusan, L., Lacourcière, Y., Monfette, G., LaBerge, J., Emond, J., Fazekas, A. T. A., Raynaud, J., et al. (1982) · PubMed · Cited by 276
Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III eortc trial (30853)
Denis, L. J., Carneiro De Moura, J. L., Bono, A., Sylvester, R., Whelan, P., Newling, D., & Depauw, M. (1993) · Urology · doi:10.1016/0090-4295(93)90634-m · Cited by 257
Comprehensive Textbook of Genitourinary Oncology
Burch, P. A. (1997) · Mayo Clinic Proceedings · doi:10.4065/72.4.384 · Cited by 235
Reporting standards and research strategies for controlled trials
Mosteller, F., Gilbert, J. P., & McPeek, B. (1980) · Controlled Clinical Trials · doi:10.1016/s0197-2456(80)80006-7 · Cited by 206
Caubet, J.-F., Tosteson, T. D., Dong, E. W., Naylon, E. M., Whiting, G. W., Ernstoff, M. S., & Ross, S. D. (1997) · Urology · doi:10.1016/s0090-4295(96)00325-1 · Cited by 204
'Early warning systems' for identifying new healthcare technologies.
Robert, Stevens, & Gabbay (1999) · Health Technology Assessment · doi:10.3310/hta3130 · Cited by 189
Principles and Practice of Genitourinary Oncology
Burch, P. A. (1998) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)63667-7 · Cited by 170
Meta-analysis of Multitreatment Studies
Hasselblad, V. (1998) · Medical Decision Making · doi:10.1177/0272989x9801800110 · Cited by 165
Self-citationCost-Effectiveness of Androgen Suppression Therapies in Advanced Prostate Cancer
Bayoumi, A. M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.21.1731 · Cited by 165
Labrie, F., Dupont, A., Bèlanger, A., Giguère, M., Lacoursiere, Y., Emond, J., Monfette, G., & Bergeron, V. (1985) · Journal of Steroid Biochemistry · doi:10.1016/s0022-4731(85)80024-8 · Cited by 152
Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial
Moinpour, C. M., Lovato, L. C., Yee, M., Blumenstein, B. A., Savage, M. J., Troxel, A. B., Eisenberger, M. A., Veith, R. W., Higgins, B., Skeel, R. T., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.20.1537 · Cited by 149
Health-related quality of life among patients with metastatic prostate cancer
Albertsen, P. C., Aaronson, N. K., Muller, M. J., Keller, S., & Ware, J. E. (1997) · Urology · doi:10.1016/s0090-4295(96)00485-2 · Cited by 146
Self-citationSchellhammer, P. F., Sharifi, R., Block, N. L., Soloway, M. S., Venner, P. M., Patterson, A. L., Sarosdy, M. F., Vogelzang, N. J., Schellenger, J. J., & Kolvenbag, G. J. C. M. (1997) · Urology · doi:10.1016/s0090-4295(97)00279-3 · Cited by 146
Dijkman, G. A., Janknegt, R. A., de Reijke, T. M., & Debruyne, F. M. J. (1997) · The Journal of Urology · doi:10.1097/00005392-199707000-00051 · Cited by 145
Bennett, C., Tosteson, T., Schmitt, B. P., Weinberg, P. F., Ernstoff, M. S., & Ross, S. D. (1999) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500265 · Cited by 109
Self-citationRobinson, M. R. G., SMITH, P. H., Richards, B., Newling, D., Pauw, M. D., & Sylvester, R. J. (1995) · European Urology · doi:10.1159/000475067 · Cited by 101
Tyrrell, C., Altwein, J. E., Klippel, F., Varenhorst, E., Lunglmayr, G., Boccardo, F., Holdaway, I. M., Haefliger, J.-M., Jordaan, J. P., Sotarauta, M., et al. (1991) · The Journal of Urology · doi:10.1016/s0022-5347(17)38080-1 · Cited by 99
Iversen, P., Christensen, M. G., Friis, E., Hornbøl, P., Hvidt, V., Iversen, H., Klarskov, P., Krarup, T., Lund, F., Mogensen, P., et al. (1990) · Cancer · doi:10.1002/cncr.1990.66.s5.1058 · Cited by 78
Boccardo, F., Pace, M., RUBAGOTTI, A., Guarneri, D., DeCensi, A., Oneto, F., Martorana, G. E., Giuliani, L., Selvaggi, F. P., Battaglia, M., et al. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80293-x · Cited by 77
Quality of life in patients with prostatic cancer a feasibility study
da Silva, F. C., Reis, E. A., Costa, T., & Denis, L. J. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3+<1138::aid-cncr2820711436>3.0.co;2-7 · Cited by 74
A Controlled Trial of Castration With and Without Nilutamide in Metastatic Prostatic Carcinoma
Beland, G. A., ELHILALI, M. M., Fradet, Y., Laroche, B., Ramsey, E. W., Trachtenberg, J., Venner, P. M., & Tewari, H. D. (1990) · Cancer · doi:10.1002/cncr.1990.66.s5.1074 · Cited by 51
History of LHRH agonist and combination therapy in prostate cancer
Labrie, F., Bèlanger, A., Cusan, L., Labrie, C., Simard, J., Luu-The, V., Diamond, P., Gomez, J.-L., & Candas, B. (1996) · Endocrine Related Cancer · doi:10.1677/erc.0.0030243 · Cited by 46
Namer, M., Toubol, J., Caty, A., Couette, J. E., Douchez, J., Kerbrat, P., & Droz, J. (1990) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(90)90442-n · Cited by 34
Zalcberg, J. R., Raghaven, D., Marshall, V. R., & Thompson, P. J. (1996) · British Journal of Urology · doi:10.1046/j.1464-410x.1996.01517.x · Cited by 28
Combined androgen blockade for the treatment of metastatic cancer of the prostate
Schellhammer, P. F. (1996) · Urology · doi:10.1016/s0090-4295(96)00002-7 · Cited by 27
Evaluation of Total versus Partial Androgen Blockade in the Treatment of Advanced Prostatic Cancer
Schulze, H., Kaldenhoff, H., & Senge, T. (2010) · Urologia Internationalis · doi:10.1159/000281336 · Cited by 18
Combination Treatment versus LHRH Alone in Advanced Prostatic Cancer
Ferrari, P., Castagnetti, G., Ferrari, G. C., Baisi, B., & Dotti, A. (2010) · Urologia Internationalis · doi:10.1159/000282863 · Cited by 17
Bono, A. V., DiSilverio, F., della Cuna, G. R., Benvenuti, C., Brausi, M. A., Ferrari, P., Gibba, A., Galli, L., & and Members of the Italian Leuprorelin Group (1998) · Urologia Internationalis · doi:10.1159/000056541 · Cited by 16
Combined Androgen Blockade in the Treatment of Advanced Prostate Cancer–an Overview
Iversen, P. (1997) · Scandinavian Journal of Urology and Nephrology · doi:10.3109/00365599709070342 · Cited by 6
Cited by
EAU Guidelines on Prostate Cancer
Heidenreich, A., Aus, G., Bolla, M., Joniau, S., Matveev, V. B., Schmid, H. P., & Zattoni, F. (2008) · European Urology · doi:10.1016/j.eururo.2007.09.002 · Cited by 3,136
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y.-H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., Wong, Y.-N., Hahn, N., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,896
Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis
Popat, S., Hubner, R., & Houlston, R. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.086 · Cited by 1,830
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Locke, J. A., Guns, E. S., Lubik, A. A., Adomat, H. H., Hendy, S. C., Wood, C. A., Ettinger, S. L., Gleave, M. E., & Nelson, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5997 · Cited by 747
Metadata
- Authors
- Samson, D. J., Seidenfeld, J., Schmitt, B., Hasselblad, V., Albertsen, P. C., Bennett, C. L., Wilt, T. J., & Aronson, N.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2002-07-11
- Volume
- 95
- Issue
- 2
- Pages
- 361-376
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2032649515
- Cited by
- 259
- References
- 37
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.